Analysts Set CeriBell (NASDAQ:CBLL) Price Target at $32.60

CeriBell (NASDAQ:CBLL) has earned a consensus recommendation of “Buy” from the six ratings firms that are covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $32.60.

CBLL has been the topic of several analyst reports. Canaccord Genuity Group initiated coverage on CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $30.00 price target on the stock. William Blair initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued an “outperform” rating on the stock. Canaccord Genuity Group upped their price objective on shares of CeriBell from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. JPMorgan Chase & Co. initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price objective on the stock. Finally, Bank of America initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price objective on the stock.

CeriBell Trading Up 0.8 %

Shares of CBLL opened at $22.15 on Thursday. The firm’s 50-day moving average is $23.74. CeriBell has a twelve month low of $18.69 and a twelve month high of $32.75.

Institutional Trading of CeriBell

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Woodline Partners LP purchased a new stake in CeriBell in the fourth quarter worth approximately $2,588,000. Yu Fan purchased a new stake in CeriBell in the fourth quarter worth approximately $31,631,000. TPG GP A LLC purchased a new stake in CeriBell in the fourth quarter worth approximately $102,677,000. RTW Investments LP purchased a new stake in CeriBell in the fourth quarter worth approximately $3,882,000. Finally, Red Tree Management LLC purchased a new stake in CeriBell in the fourth quarter worth approximately $57,083,000.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.